Background. Treatment guidelines recommend the use of a single dose of benzathine penicillin G (BPG) for treating early syphilis in human immunodeficiency virus (HIV)-infected persons. However, data supporting this recommendation are limited. We examined the efficacy of single-dose BPG in the US Military HIV Natural History Study.
Current treatment guidelines recommend the use of a single dose of 2.4 million units (MU) of benzathine penicillin G (BPG) for the treatment of early stages of syphilis regardless of human immunodeficiency virus (HIV) serostatus; however, compliance with this recommendation is variable [1] . In a recent survey, infectious disease consultants belonging to a sentinel network were questioned about their syphilis treatment practices [2] . The survey focused on areas of uncertainty and with limited evidence to guide practice, such as the management of HIV-infected individuals with secondary syphilis. Contrary to the recommendations, most respondents (62%) preferred the use of 3 doses of BPG (administered weekly) for the treatment of secondary syphilis in HIV-infected individuals [2] . The reluctance to use a single dose of BPG to treat early syphilis cases in HIV-infected persons probably relate to several well-recognized features of this infection and the recommended treatment. For one, cerebrospinal fluid abnormalities (in the absence of symptoms) are a common finding in both HIV-infected and uninfected individuals with primary, secondary, and early latent disease [3, 4] . Second, standard doses of BPG fail to achieve treponemicidal concentrations in the cerebrospinal fluid, leading to concerns about the adequacy of a single dose of BPG for the treatment of a disease that even in the earliest stages is widely disseminated and often involves the central nervous system [5] [6] [7] [8] . Finally, data that support the use of a single dose of BPG in early syphilis are primarily from the pre-HIV era [9] [10] [11] . There is a paucity of information that supports the use of 1 dose of BPG to treat early syphilis in HIV-infected persons [12] . Hence, to assess the adequacy of the current recommendation, we performed a study designed to examine whether or not the dose and duration of BPG are significant modifiers of serologic response to treatment.
METHODS

Study Population
To achieve our objectives, we used data from the US Military HIV Natural History Study (NHS), a cohort comprised of Department of Defense beneficiaries [13] . NHS visits are conducted every 6 months during which participants undergo blood draws, are examined by a physician, and are interviewed by research personnel. During these interviews and through the abstraction of medical records, research personnel collect clinical information (to include syphilis diagnoses), syphilis treatment history, and results of testing performed outside the participating military treatment facilities. This substudy included participants followed in the NHS between 1 January 1986 and 27 August 2013. NHS participants with early syphilis were included if the episode met serologic criteria for syphilis (ie, a positive nontreponemal [NTr] test that was confirmed by treponemal testing), and if treatment, pretreatment, and posttreatment NTr titers drawn within 13 months of treatment were available.
Data Analysis and Definitions
Syphilis screening is performed using a NTr test, primarily the rapid plasma reagin (RPR) test. Positive NTr tests are confirmed using a licensed treponemal test. Before 2006, screening for syphilis was conducted in accordance with the policies of the military treatment facilities; since 2006, annual serologic testing has been incorporated in the NHS.
Syphilis staging has not been captured consistently in the NHS; hence, we used duration of syphilis infection as an approximation. We defined cases as "early" if there was a documented seroconversion (ie, from a negative to a positive NTr test) in the preceding 365 days. A single subject could contribute >1 case to this analysis, provided treatment and response to treatment for each case were clearly documented in the database (ie, following treatment a ≥4-fold decline in NTr titer was achieved at any time point thereafter, followed by a ≥4-fold increase in titer). Because behavioral data is difficult to ascertain, this definition has been used by some experts to discern relapse from reinfection [14] . To be considered an early case, the increase from the nadir titer was required to have occurred within 365 days. Subjects who did not respond to their initial treatment regimen could not contribute >1 case.
A case was considered treated if the treatment was administered within 6 weeks of the positive NTr titer. Response to treatment was defined as a ≥4-fold decline in NTr titer following 1 course of treatment. Among subjects whose pretreatment titer was ≤1:4, response to treatment was defined by seroreversion (ie, a switch from a positive to a negative NTr test). To categorize treatment response, we assessed response at 13 months instead of the recommended 365 days to allow for inclusion of subjects whose visits were delayed. We used the highest titer (in the 6 months preceding or in the 30 days after completion of treatment) to assess treatment response [15] . In this analysis, Figure 1 . Graphical representation of the cases selected for this analysis. Although subjects could contribute >1 case to this analysis, subsequent cases were not included if treatment was not recorded for the preceding case. For this figure, response was assessed at 13 months following treatment.
variables related to demographics (age, sex, ethnicity), HIV parameters (time updated CD4 counts, HIV RNA levels, and antiretroviral therapy use), and syphilis-specific variables (treatment regimen and pretreatment NTr titers) were examined. Highly active antiretroviral therapy (HAART) was defined as the use of 3 or more drugs belonging to ≥2 classes of antiretrovirals or the use of a triple-nucleotide regimen [16] . We categorized syphilis treatment as regimens that used BPG exclusively (ie, 1 or ≥2 doses of BPG only), or "other" regimens. Other regimens included penicillin-containing regimens, that is, where a penicillin derivative was used either alone or in combination with BPG or non-penicillin-containing regimen (eg, doxycycline, azithromycin, or ceftriaxone).
Statistical Methods
Descriptive statistics were used to describe the population. Univariate P value statistics for categorical factors were calculated using χ 2 or Fisher exact test depending on cell count. For continuous variables, t tests and Wilcoxon tests were used, respectively, for variables with normal and nonnormal distribution.
Baseline for this analysis was defined as the date of treatment. Follow-up time was calculated from the start of therapy. The latest follow-up date was 27 August 2013.
Multivariate Cox proportional hazards models were used to assess factors associated with time to treatment response. Cases were censored at the time of their second course of treatment for the same episode, at last record of RPR titer, or death. Covariates were included based on clinical importance. These models were adjusted for within patient clustering. Significance of the multivariate model was set at P < .05; all P values are 2-sided. Hazard rates and ratios are presented with 95% confidence intervals (CIs). Analyses were conducted using the R package version 2.13.2.
To evaluate the effect of missing data (25% of all cases) we performed 2 sensitivity analyses. In the first, we evaluated syphilis cases after 1 January 2006. This date was chosen as routine syphilis screening was incorporated in the NHS after 1 January 2006, allowing for a more complete dataset. In the second, as missing pretreatment titers resulted in the exclusion of 14% of the cases, we used the first documented titer in lieu of the pretreatment titer. To evaluate whether the inclusion of multiple cases per subject affected our results, we performed an analysis restricted to subjects who contributed a single case. Finally we performed a sensitivity analysis to examine the effect of intercurrent antibiotics on treatment response.
RESULTS
Study Population
Of the 5530 NHS participants who had at least 1 evaluable NTr test, 743 subjects (13.4%) met serologic criteria for syphilis infection. A total of 1042 cases of syphilis were recorded; 619 cases met criteria for early syphilis. Treatment response could be assessed in more than three-quarters of the cases (N = 478) and are included in this analysis. Sixty-three cases were excluded because treatment was not documented; 78 cases were omitted because the response could not be assessed due to missing preand/or posttreatment NTr titers ( Figure 1 ). 
Characteristics of Syphilis Cases
The clinical characteristics of the 478 syphilis cases are illustrated in Table 2 . A total of 141 (29%) of the studied cases were treated with 1 dose of BPG, whereas 252 (53%) cases were treated with ≥2 doses of BPG. Other regimens were used to treat 85 
Serologic Response to Treatment
Four hundred thirty-four cases (91%) had responded to treatment by 13 months and 97% of the cases examined had responded to therapy by 24 months (Table 3 ). The median time to treatment response was about 5 months ( Figure 2 ). KaplanMeier curves were utilized to examine the effect of the different treatment regimens on the time to treatment response. Response to treatment did not vary by regimen (log-rank test, P = .59; Figure 2 ). were not associated with response to treatment ( Table 4 ). The results of the different sensitivity analyses were similar; the dose and duration of BPG use did not alter response to treatment (Supplementary Tables 1-3 ).
Factors Associated With Treatment Response
DISCUSSION
We examined treatment responses in 478 cases of early syphilis in HIV-infected persons, including 141 cases treated with a single dose of BPG. Following treatment, 91% of the included cases exhibited serologic response by 13 months and 97% by 2 years. A systematic review of the literature suggests that between 1% and 22% of HIV-infected subjects treated for early syphilis fail therapy [17] . Response rates observed in our study fall within this range and are identical to the rates observed in 2 recent studies [18, 19] .
Furthermore, the results of our study suggest that the response to therapy does not vary by regimen type. We are aware of 4 other studies that have examined the effects of dose and duration of BPG treatment on treatment responses in HIV-infected persons with early syphilis [12, 18, 20, 21] . In a randomized double-blind trial, conducted in the pre-ART era, 541 subjects with early syphilis were randomized to receive standard treatment (ie, a single dose of 2.4 MU of BPG) or high-dose therapy (standard treatment followed by a 10 days of amoxicillin and probenecid) [12] . In this study, treatment responses were similar in both arms. Whereas these results form the basis of our current recommendation, only 19% of the enrolled subjects were HIVinfected, and losses to follow up were substantial (about 50% at 1 year), reducing the applicability of these results. In the HAART era, 3 studies have examined the question [18, 20, 21] . In 2 studies, the regimen type appeared not to matter [18, 20] . However, both studies included small numbers of subjects who received 1 dose of BPG as therapy and were likely underpowered to demonstrate small differences [18, 20] . In one study, 4 of 129 HIV-infected subjects received a single dose of BPG [20] , whereas in the other study, 47 (8%) subjects were treated with a single dose of BPG [18] . In comparison, about a third of our cases (n = 141) received a single dose of BPG; this number exceeds the combined total reported in the 3 prior studies (n = 92). Hence, we believe this study represents a significant addition to the limited body of literature examining this issue.
Finally, unpublished data from a third prospective study suggest that individuals treated with 3 doses of BPG have a superior response to treatment [21] . However, when the analysis was restricted to subjects exhibiting an initial response (ie, a 4-fold decline in NTr titer), response to therapy did not vary by treatment regimen. In this study, subjects exhibiting a 4-fold decline in NTr titer followed by a 4-fold increase were considered treatment failures. Thus, misclassification of cases may have occurred with subjects been classified as nonresponders when they were in fact reinfected [21] .
In our study, older age, lower CD4 count, and NTr titer <1:64 were associated with delayed responses. While contextualizing our results, it is important to consider distinguishing characteristics of our cohort. For one, HIV-infected persons with syphilis had fairly preserved immune function (median CD4 count was 494 cells/µL) and low viral loads at syphilis diagnosis (median viral load, 1.9 log 10 copies/mL). In addition, HAART use was common at syphilis diagnosis (nearly two-thirds were on HAART). These HIV-related factors individually and in combination have been associated with superior responses to therapy [18, 19, [22] [23] [24] . The association with CD4 count observed in our study is worth noting, as about half the subjects had CD4 counts >500 cells/µL at syphilis diagnosis. This observation suggests that ongoing immune restoration in subjects with relatively high CD4 count is associated with superior response to therapy and advocates for the universal use of antiretroviral therapy. We did not observe a relationship with HAART use, perhaps because HAART use is common in the NHS (two-thirds reported HAART use at syphilis diagnosis). In sum, our results suggest that there would be little benefit to using additional doses of BPG for the treatment of early syphilis in HIV-infected persons with preserved CD4 counts and low viral loads; however, our study is not adequately powered to answer the question in individuals with advanced immunosuppression. Future studies should focus on this group of individuals.
Strengths of this analysis include the large sample size examined, and the close follow-up of our participants. Limitations of our study were common to other similar studies of this design.
We excluded approximately 25% of the cases due to missing information. To account for the missing cases, we performed sensitivity analyses; these results suggest that the missing cases would not have altered our conclusions. In addition, our exclusion rate was significantly less than other studies, where it has ranged from 38% to 52% [12, 19, 24] . Our results nonetheless suggest that retention and follow-up remain a challenge even in a setting where individuals have free access to care. This was a retrospective study, and therefore could not be controlled for residual confounding, selection biases, or laboratory variations in NTr titers as the samples were not batched. Also, it is important to note that clinical symptoms are not captured in the NHS; hence, our definition excludes individuals with symptomatic relapses. To examine the possibility that treatment assignment was nonrandom and influenced by the health status of the patient, we evaluated factors associated with treatment choices (data not shown). The choice of treatment was influenced only by the year a case was diagnosed (recent syphilis cases were more likely to be treated with 1 dose of BPG) and not by other demographic or HIV-related variables. Treatment recommendations have varied over the 28-year period of this study. Recent guidelines recommend a single dose of BPG for treating early syphilis, treatment choices in the NHS appear to pattern these recommendations, and a selection bias appears unlikely. Prospective studies designed to examine this question are needed. Finally, in the absence of behavioral data, distinguishing relapse from reinfection is complicated and is often based on expert consensus. Some experts have suggested that late increases in NTr titers (ie, those that occur >365 days after treatment for early syphilis) are suggestive of reinfection rather than relapse [22, 25] . In our study, among patients who had a rise in titer after a documented response, the median time period between these measurements was 1.7 years, thereby favoring reinfection as the most likely mechanism. Additionally, most subjects had an intervening documented negative NTr test between their cases, again favoring reinfection as the mechanism.
In conclusion, the results of our study support the use of a single dose of BPG for the treatment of early syphilis in HIVinfected persons with preserved CD4 counts. Overall, serologic failure is uncommon. When close follow-up can be ensured, HIV-infected persons with preserved CD4 counts and delayed NTr responses can be followed safely for a year and perhaps even 2 years without additional treatment courses.
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